SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000947871-14-000034
Filing Date
2014-01-22
Accepted
2014-01-22 15:22:37
Documents
1
Group Members
DOMINIQUE SEMONMERLIN BIOMED PRIVATE EQUITY ADVISORS, LLCMERLIN NEXUS III, L.P.NEXUS GEMINI, L.P.

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 6 ss199858_sc13ga.htm SC 13G/A 144615
  Complete submission text file 0000947871-14-000034.txt   146368
Mailing Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080 650-266-3500
SUNESIS PHARMACEUTICALS INC (Subject) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-81034 | Film No.: 14540221
SIC: 2834 Pharmaceutical Preparations

Mailing Address 230 PARK AVE, SUITE 928 NEW YORK NY 10169
Business Address 230 PARK AVE, SUITE 928 NEW YORK NY 10169 646-227-5270
Merlin BioMed Private Equity Advisors, L.L.C. (Filed by) CIK: 0001429303 (see all company filings)

IRS No.: 000000000
Type: SC 13G/A